In the last 25 years, several studies have tried to assess whether this could be replaced by oral supplementation
This strategic approach allows you to address multiple aspects of health optimization simultaneously
discontinued CJC-1295 (DAC) Not FDA-approved Feature Phase III Trial Data Tesamorelin Yes (n=816 pooled) Sermorelin No adult Phase III VAT datasets CJC-1295 (DAC) No Feature Visceral Fat Reduction Tesamorelin 15-20% at 26 weeks Sermorelin Not formally studied in RCTs CJC-1295 (DAC) Not formally studied in RCTs Feature Liver Fat Reduction Tesamorelin 32% at 12 months (NAFLD trial) Sermorelin Not studied CJC-1295 (DAC) Not studied Feature Typical Research Dose Tesamorelin 2 mg daily Sermorelin 200-300 mcg nightly CJC-1295 (DAC) 1-2 mg weekly Feature Unique Advantage Tesamorelin Only FDA-approved GHRH with deepest trial evidence Sermorelin Longest historical track record CJC-1295 (DAC) Weekly dosing convenience Tesamorelin is the only GHRH peptide with active FDA approval and validated Phase III visceral-fat data
For neuroregeneration, both peptides sit at the lower rungs of this ladder rodent models and in-vitro systems with no randomized controlled trials in any neurological indication for either
Affinity tags such as glutathione S-transferase (GST), histidine (HIS), and others have revolutionized the purification of proteins with both known and unknown biochemical properties
Many of the diseases that cause dehydration in adults flush fluid out through diarrhea, vomiting, sweating, or excess urination, and some quietly disrupt the hormones that tell the kidneys to hold onto water
